Our experts weigh in on why they like Vertex Pharmaceuticals, Neuralstem, and Intercept Pharmaceuticals.
News & Analysis: Neuralstem
Neuralstem, Inc., Depomed Inc., and Xoma Corp. have news that could move them this year.
Achillion Pharmaceuticals Inc., Neuralstem Inc., and Prothena Corp. Plc could all announce news this year that could make shares climb or fall.
Neuralstem, Inc shares jumped after Brean Capital analysts issued a bullish outlook.
Find out which companies got the best clinical results for the week ending March 28, 2014.
Neuralstem shares jumped after reporting another positive study involving its lead pipeline product, NSI-566, in rats. Can shares head even higher?
Neuralstem soars after publishing its final phase 1 data for NSI-566. Should shareholders be cheering or jeering this news?
A look back at the biggest stories this week in biotech and what they mean for investors.
NSI-566 has already shown promise in ALS and rat models of spinal cord injuries.
A weekly adventure in giving unknown companies some attention.